BioLife Solutions Reports Second Quarter 2025 Financial Results

Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62%and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million […]

Hims & Hers Health, Inc.: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

Hims & Hers Health, Inc.: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion. GlobeNewswire August 07, 2025 Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) — The Portnoy Law

Dorchester Minerals, L.P. Announces Second Quarter Results

(NASDAQ:DMLP), DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) — Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership's net income for the quarter ended June 30, 2025 of $12,347,000, or $0.25 per common unit. A comparison of the Partnership's consolidated results for the quarters ended June 30, 2025 and 2024 are set forth below: Three

Health Catalyst Reports Second Quarter 2025 Results

(NASDAQ:HCAT), SALT LAKE CITY, Aug. 07, 2025 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025. “For the second quarter of 2025, I am pleased by our strong financial results,

Progyny, Inc. Announces Second Quarter 2025 Results

(NASDAQ:PGNY), Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the

Health Catalyst Reports Second Quarter 2025 Results

Health Catalyst Reports Second Quarter 2025 Results GlobeNewswire August 07, 2025 SALT LAKE CITY, Aug. 07, 2025 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025. “For the second quarter

Progyny, Inc. Announces Second Quarter 2025 Results

Progyny, Inc. Announces Second Quarter 2025 Results GlobeNewswire August 07, 2025 Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement NEW YORK, Aug. 07, 2025

Dorchester Minerals, L.P. Announces Second Quarter Results

Dorchester Minerals, L.P. Announces Second Quarter Results GlobeNewswire August 07, 2025 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) — Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership's net income for the quarter ended June 30, 2025 of $12,347,000, or $0.25 per common unit. A comparison of the Partnership's consolidated results for the quarters ended

ThreeSixty Journalism Concludes 2025 Storytelling Institute for Local Students

ST. PAUL, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) — ThreeSixty Journalism has successfully concluded its 2025 Multimedia Storytelling Institute, a three-week summer camp held July 7 through July 24 at the University of St. Thomas College of Arts and Sciences. The program brought together 18 high school students interested in journalism and media careers to

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

(NasdaqGM:IOVA), $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi(R) in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering

Scroll to Top